Defining pluripotent stem cells
===============================

Discovery of pluripotent stem cells - embryonal carcinoma cells
---------------------------------------------------------------

Pluripotency is the potential of stem cells to give rise to any cell of the embryo proper. The study of pluripotent stem cells from both mouse and human began with the study of teratocarcinomas, germ cell tumours that occur predominantly in the testis and constitute the most common cancer of young men. In 1954, Stevens and Little \[[@B1]\] found that males of the 129 mouse strain developed testicular teratocarcinomas at a significant rate. This finding opened the way for detailed studies of these peculiar cancers, which may contain a haphazard array of almost any somatic cell type found in the developing embryo \[[@B2]\]. The stem cells of these tumours are embryonal carcinoma (EC) cells, which express characteristics, including a developmental potential, similar to those of the inner cell mass (ICM) of the early embryo \[[@B3]\]. Experience with these pluripotent malignant EC cells from mouse teratocarcinomas provided the basis for the derivation of embryonic stem (ES) cells from explants of mouse blastocysts independently \[[@B4],[@B5]\]. Indeed, mouse EC and ES cells closely resemble one another, expressing similar markers and, in some cases, similar developmental potentials, although a report of germ line derivation from mouse EC cells in chimeras \[[@B6]\] has never been confirmed.

Pluripotent cells in the embryo - inner cell mass cells
-------------------------------------------------------

At the morula stage, totipotent cells start to specialize as they form the blastocyst, comprising an outer layer of cells, the trophectoderm (TE), and a group of pluripotent cells, the ICM. While the TE will develop into placental tissues, the ICM gives rise to all cells of the embryo proper as well as several extraembryonic tissues. The earliest factors known to regulate the formation of pluripotent ICM cells are OCT4 and NANOG \[[@B7]-[@B9]\]. Without OCT4, epiblast cells fail to form and ES cells cannot be derived, while NANOG is required for the germline formation \[[@B7]-[@B9]\].

Recent studies in the laboratory mouse have provided insights into the molecular mechanisms and key factors regulating the specification of ICM and TE lineages. At the morula stage, cells choose their fate depending on their position and polarity \[[@B10]\]. In outside cells, Yap, the co-activator for transcription factor Tead4, localises in the nucleus and increases Tead4 activity. Tead4 subsequently activates the TE master factor Cdx2, which determines the cell fate \[[@B10]\]. Embryos lacking either Tead4 or Cdx2 fail to produce functional trophecto-dermal tissue but ICM cells remain intact and ES cells can be derived \[[@B11],[@B12]\]. The dominance of Cdx2 suppresses Oct4 expression in the outer cells and restricts its expression in the inner cells, which become ICM cells at the blastocyst stage. Thus, the counter-activity between Oct4 and Cdx2 allows the segregation of the first two embryonic lineages \[[@B13]\]. It is noteworthy that this mechanism might be specific to mouse as in both rhesus monkey and human, the expression of NANOG is reported to be restricted to the ICM, but OCT4 was detected in TE as well as ICM cells \[[@B14]\].

Embryonic stem cells and species differences
--------------------------------------------

Although human ES cells were not derived until 1998 \[[@B15]\], studies of EC cells from human testicular cancers demonstrated significant differences between mouse and human EC cells and, by implication, ES cells \[[@B16]-[@B19]\]. Most notably, the cell surface antigens SSEA1 and SSEA3 and 4 are expressed differently: mouse EC and ES cells are SSEA1(+)/SSEA3(-)/SSEA4(-), whereas human EC cells are SSEA1(-)/SSEA3(+)/SSEA4(+). This surface antigen phenotype of human EC cells is similar to that of human ES cells \[[@B15],[@B20]\] and human ICM cells \[[@B21]\]. A large panel of surface antigen markers and characteristic gene expression patterns for human ES cells has now been identified \[[@B20]\]. A further distinction between human and mouse ES cells, which was also evident in EC cells, is the capacity of human EC and ES cells to generate trophoblastic cells \[[@B16]\]. This does not usually occur in mouse EC and ES cells, except after genetic manipulation \[[@B13]\]. Especially in the mouse, a clear distinction between ES cells and epiblast stem cells is being made \[[@B22]-[@B24]\]. Recent work with human induced pluripotent stem (iPS) and ES cells has produced cells more similar to mouse ES cells by maintenance in low oxygen conditions, or overexpression of *OCT4*, *KLF4*and *KLF2*and inhibition of glycogen synthase kinase 3 and mitogen activated protein kinase \[[@B25],[@B26]\]. These culture conditions with physiological oxygen levels (5%) are able to maintain more naïve ES cells \[[@B26]\]. However, it remains to be seen if this reduction of oxidative stress is important for the use of pluripotent stem cells in therapeutic applications.

Inducing pluripotent stem cells from somatic cells
==================================================

The history of reprogramming
----------------------------

Through early embryonic development and cellular differentiation, cells progressively lose developmental potency and choose a specific fate \[[@B27]\]. However, the seminal somatic cell nuclear transfer studies of Briggs and King \[[@B28]\] showed that blastula cell nuclei retain the genetic information required for pluripotency when injected into enucleated frog oocytes. This phenomenon was investigated further by Gurdon and Uehlinger \[[@B29]\], who demonstrated that even more differentiated intestinal cells were capable of directing development into adult frogs following somatic cell nuclear transfer, albeit at low efficiency (approximately 1%). These early cloning experiments proved that nuclei from terminally differentiated cells are capable of generating viable cloned animals, and formed the basis of later mammalian cloning experiments \[[@B30]\].

The creation of the first cloned sheep, \'Dolly\', by Wilmut and colleagues \[[@B30]\] together with many other later successful mammalian cloning attempts convincingly demonstrated that the developmental restrictions established during differentiation are due to reversible changes in the epigenome, rather than to permanent modifications to the genome \[[@B31]\]. Fusing somatic cells with ES cells or exposing them to EC cell extracts can also generate cells with pluripotent phenotypes \[[@B32],[@B33]\]. Thus, the cytoplasm of the oocyte and pluripotent stem cells must contain factors necessary for reprogramming. These studies indicate that key factors that are important for pluripotency within germ cells, early embryos and ES cells may also have the reprogramming ability.

Studies with somatic cells demonstrated that one could redirect cell fate by forced expression of a single lineage-specific transcription factor. Weintraub and colleagues \[[@B34]\] found that overexpression of *MyoD*is sufficient to convert fibroblasts into muscle cells, while mature B cells can be reprogrammed into macrophages by enforced expression of C/EBPα or C/EBPβ within 3 to 4 days \[[@B35]\]. These studies highlighted the possibility that trans-differentiation or even dedifferentiation may be mediated by a few defined factors.

Induced pluripotency with key factors
-------------------------------------

In 2006, the ground breaking work by Takahashi and Yamanaka \[[@B36]\] demonstrated that forced expression of four ES cell factors (*Oct4*, *Sox2*, *cMyc*, and *Klf4*) in fibro-blast cells can reprogram them to a pluripotent state. The most efficient method to make iPS cells is through viral transduction due to their high integration efficiency \[[@B37],[@B38]\]. In properly reprogrammed iPS cells, the transgene driven by the viral promoter should be completely silenced \[[@B39]\]. Failure of silencing indicates incomplete reprogramming and raises the danger of carcinogenesis by the oncogene *cMyc*\[[@B39]\]. To avoid insertional mutagenesis and transgene reactivation, associated with the viral approach, other methods that do not alter the genome have been developed, such as non-integrating episomal vectors \[[@B40]\], minicircle vectors \[[@B41]\] and the PiggyBac transposon system \[[@B42],[@B43]\]. Transgene-free iPS cells were successfully derived but with lower efficiency. The most attractive approach may be using permeable recombinant proteins \[[@B44]-[@B46]\], as this eliminates the possibility of genome alteration by introduced foreign DNA. This would also allow the dosage to be controlled and the exposure time of each factor optimised, although this method has not been widely successfully applied.

Molecular mechanisms of reprogramming
-------------------------------------

Re-establishing pluripotency in a somatic cell is a complicated process. The most important changes include the activation of an ES-cell-specific transcription network, re-setting the epigenetic landscape, alteration of the cell cycle signature and overcoming the DNA damage response triggered by these drastic changes.

### ES-cell-specific transcription factors and transcription network

The four reprogramming factors discovered by Takahashi and Yamanaka, *Oct4*, *Sox2*, *Klf4*and *cMyc*, all have vital roles in early embryogenesis and ES cells \[[@B36]\]. The POU domain transcription factor *Oct4*is required for the pluripotency of ICM cells and ES cells and is an essential factor in most reprogramming experiments \[[@B7]\]. Although in one recent report the nuclear receptor Nr5a2 was able to replace Oct4, the underlying mechanism appeared to be that Nr5a2 activates *Oct4*and *Nanog*by binding to their promoters and upregulating their expression \[[@B47]\]. A protein interaction study in mouse ES cells showed that Oct4 binds to as many as 92 proteins. Many of these are only expressed by ES cells, but some are ubiquitously expressed in all cells, such as the nucleosome remodelling and deacetylase (NuRD) complex \[[@B48]\]. The cellular protein environment can have a significant influence on reprogramming. For example, when fusing a somatic cell with an ES cell, or transfering its nucleus into an oocyte, where many OCT4 binding partners naturally exist, reprogramming is much quicker and more efficient \[[@B32],[@B49]\]. By choosing adult cell types that express more OCT4 interacting proteins, such as neural stem cells and melanocytes where SOX2, a Sry-related high mobility group box transcription factor, is present, one can obtain iPS cells with higher efficiency and in a shorter time frame \[[@B50],[@B51]\].

In mouse ES cells, it has been shown that Sox2 closely works with Oct4 to regulate the transcription of key pluripotency genes, including *Oct4*, *Sox2*and *Nanog*\[[@B52]\]. Without Sox2, ES cells cannot effectively activate the Oct-Sox enhancers. However, higher levels of Oct4 were able to compensate for the absence of Sox2 and maintain the ES cell phenotype \[[@B52]\]. During reprogramming of mouse fibroblast cells, Sox2 can be replaced by transforming growth factor-β inhibitors, which have been shown to induce both *Nanog*and *cMyc*expression \[[@B53],[@B54]\]. Thus, it appears that Oct4 could work with factors other than Sox2 to achieve cellular reprogramming.

The Krüppel-like zinc finger transcription factor Klf4 is highly expressed by mouse ES cells and can cooperate with the Oct4-Sox2 complex to activate certain ES-cell-specific genes such as *Lefty1*\[[@B55]\]. It plays an important role in the pluripotency circuitry by regulating the expression of *Sox2*and *Nanog*\[[@B56],[@B57]\]. By overexpressing *Klf4*, mouse epiblast derived stem cells (epistem cells) can be returned to the naïve ES cell state \[[@B58]\]. Similarly, increasing the expression of KLF4 and OCT4 or KLF4 and KLF2 enabled human ES cells and iPS cells to exhibit mouse ES cell characteristics, including the ability to grow in leukemia inhibitory factor (LIF) and 2i (ERK1/2 and glycogen synthase kinase 3 inhibitors) as well as the activation of both X chromosomes \[[@B25]\]. iPS cells reprogrammed using *Oct4*, *Sox2*and *Klf4*but without *cMyc*showed lower tumorigenicity \[[@B59]\]. The above evidence suggests that *Klf4*can prompt cells to acquire a more authentic and naïve ES cell phenotype.

*cMyc*is an oncogene and seems to act as a catalyst in the reprogramming process as it can significantly increase the efficiency of iPS cell generation \[[@B59]\]. In ES cells, cMYC was found to occupy promoters of active genes and ES-cell-specific microRNAs (miRNAs), including miR-291-3p, miR-294, miR-295, miR-141, miR-200, and miR-429 \[[@B57],[@B60],[@B61]\]. Overexpression of these miRNAs either promoted iPS cell generation or reduced mouse ES cell differentiation \[[@B60],[@B61]\]. cMYC can recruit multiple chromatin remodellers, such as histone acetyl-transferase GCN5 and histone demethylase Lid, to create an open chromatin state. This allows the ectopically expressed ES cell transcription factors to activate their target genes more easily \[[@B62]\]. The negative side of cMYC\'s action is tumorigenecity \[[@B59]\]. Thus, iPS cells created using *cMyc*need to be carefully scrutinised to ensure the silence of this oncogene.

*NANOG*and *LIN28*can replace *KLF4*and *cMYC*to reprogram human fibroblast cells to iPS cells \[[@B38]\]. *Nanog*is a core member of the pluripotency circuitry \[[@B57]\] and constitutive expression is sufficient to support self-renewal of mouse ES cells in the absence of LIF \[[@B8]\]. *Nanog*is also required for germline development \[[@B63]\]. Although not absolutely required for reprogramming, including *Nanog*increased the efficiency of iPS generation \[[@B64]\].

LIN28 is an evolutionarily conserved RNA binding protein highly enriched in mouse and human ES cells \[[@B20],[@B65]\]. Its function in reprogramming will be discussed in more detail later in the section on miRNAs.

Studies in mouse ES cells revealed that the promoter region of actively transcribed genes was often occupied by multiple key pluripotency transcription factors \[[@B57]\]. Moreover, these factors can self-regulate to reinforce the undifferentiated state. Different combinations of transcription factors may control distinct subgroups of genes \[[@B57]\]. Thus, to activate the entire ES cell transcriptome, not only is the cooperation of key factors (namely OCT4, SOX2, KLF4 and cMYC) required, but their levels and ratio of expression are also critical \[[@B66]\]. Two very recent publications reported that reprogramming factors can also orchestrate a mesenchymal to epithelial transition, which is important for the initiation stage of reprogramming \[[@B67],[@B68]\]. Down-regulation of epithelial-specific factors, such as E CADHERIN, PAR3 and CRB3, suppressed the formation of iPS colonies \[[@B68]\], while suppression of transforming growth factor-β signalling, which is important for epithelial to mesenchymal transition, improved reprogramming efficiency \[[@B67]\].

### Epigenetics

The chromatin and DNA modification machinery play critical roles during reprogramming as the epigenetic landscape of a somatic cell needs to be completely reshaped to ES-cell-like states. The epigenome of ES cells is characterised by the demethylation of the promoter regions of key pluripotency transcription factors, such as *Oct4*, *Sox2*and *Nanog*, as well as bivalent chromatin modifications on developmentally important transcription factors \[[@B69]\]. This ensures a high level of expression of the core factors that maintain pluripotency. At the same time cells reside in a poised state, ready to differentiate in response to developmental signals \[[@B69]\].

During reprogramming, the genome loci occupied by histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 trimethylation, which are commonly associated with active and repressive gene expression, respectively, appears to change in accordance with the dedifferentiation process. For example, H3K4me3 marking was lost from promoter regions of mouse embryonic fibroblast-specific genes, but increased significantly on the promoters/enhancers of the ES-cell-specific genes *Fgf4*, *Oct4*and *Nanog*\[[@B70]\]. Moreover, the DNA methylation was erased at promoters of pluripotency genes in fully reprogrammed cells but not in mouse embryonic fibroblasts or partially reprogrammed cells \[[@B70]\]. To date, many cell types, including some cancer cells, have been shown to be amenable for reprogramming, reflecting the plasticity of the epigenome \[[@B51],[@B64],[@B71],[@B72]\]. Different cell types may possess different degrees of plasticity; compared to skin fibroblast cells, epithelial cell types, such as keratinocytes, liver and stomach cells, can be converted to iPS cells with higher efficiency \[[@B72],[@B73]\]. In addition, a hierarchy of epigenetic states may correlate with a cell\'s differentiation stage. It was found that in the hematopoietic lineage, stem and progenitor cells give rise to iPS cells much more efficiently than terminally differentiated B and T cells \[[@B74]\]. Manipulating the DNA and chromatin modifications can greatly facilitate iPS cell formation. The DNA methyltransferase inhibitor 5\'-azacytidine and the histone deacetylase inhibitor valproic acid increased the reprogramming efficiency 5-fold and more than 100-fold, respectively \[[@B75]\]. BIX-01294, an inhibitor of the G9a histone methyltransferase, was able to substitute cMyc to induce pluripotency from neural stem cells together with *Oct4*and *Klf4*\[[@B76]\].

Two recent studies observed that early passage iPS cells still retain some degree of somatic cell memory, which can influence the differentiation preference of these cells \[[@B77],[@B78]\]. However, these remaining epigenetic memories appeared to attenuate after continuous *in vitro*culture \[[@B77],[@B78]\]. In addition, some mouse iPS cell lines displayed aberrant silencing of imprinted genes such as the *Dlk1-Dio3*cluster. These lines showed poor contribution to chimeric animals and were not germline competent \[[@B79],[@B80]\]. The ability of germline transmission is also influenced by the combination of reprogramming factors. Mouse iPS cells generated by *Oct4*, *Sox2*, *Klf4*and *Tbx3*were found to contribute to the germ tissue with higher efficiency compared to iPS cells reprogrammed by *Oct4*, *Sox2*, and *Klf4*or *Oct4*, *Sox2*, and *Esrrb*\[[@B81]\]. Imprinting abnormalities were found in human iPS cells, including the biallelic expression of H19 and KCNQ10T1 \[[@B82]\]. The Fragile X syndrome gene (FX) was active in ES cells derived from embryos with the FX mutation but remained silenced in iPS cells reprogrammed from FX-fibroblast cells \[[@B83]\]. Thus, if iPS cells and their derivatives are to be used to model human diseases or in therapeutic applications, several aspects need to be carefully evaluated: the tissue origin and passage number; the reprogramming factors used; the status of imprinted genes; and the histone modification of disease-related genome loci.

### microRNAs and reprogramming

miRNAs are approximately 22-nucleotide RNAs that bind to complementary sequences in the 3\' untranslated regions of protein coding mRNAs to regulate their degradation or translation \[[@B84]\]. As important modulators of developmental timing and stem cell differentiation, they have, unsurprisingly, also been implicated in reprogramming. The well-known *Let-7*family miRNAs are ubiquitously expressed in somatic cells and up-regulated upon ES cell differentiation. Their mRNA targets include those encoding cell cycle regulators such as K-RAS, cMYC, CDC25A, cyclinD1, and stem cell factors HMGA2, Mlin-41 and IMP-1 \[[@B82],[@B85]\]. Lin28 is an ES-cell-specific factor whose major function is to keep *let-7*miRNAs at low level by promoting their degradation \[[@B86],[@B87]\]. Indeed, an insightful study by Hanna and colleagues \[[@B64]\] showed that overexpression of *Lin28*shortened the cell cycle in monoclonal B cells and sped up iPS cell generation. In another report, the ES-cell-specific miRNA miR-294 increased the efficiency of iPS cell generation by approximately tenfold when introduced together with *Oct4*, *Sox2*and *Klf4*, but not when *cMyc*was present \[[@B60]\]. The authors then found that miR-294 was a downstream target of cMyc \[[@B60]\]. Interestingly, using a green fluorescent protein (GFP) reporter driven by the Oct4 promoter, most colonies from the *Oct4*, *Sox2*, *Klf4*and miR-294 group were positive for GFP expression, indicating that they are more homogenous iPS cell colonies. In contrast, cMyc significantly increased the number of GFP-positive as well as GFP-negative colonies when added together with *Oct4*, *Sox2*, and *Klf4*\[[@B60]\]. This study suggests that ES-cell-specific miRNAs are able to fine tune the reprogramming process and may be useful to reduce the heterogeneity in iPS cells.

### DNA damage

The cellular stress imposed by reprogramming can trigger the DNA damage response and subsequently result in cell cycle arrest and senescence. Only a few cells were able to overcome this barrier and become iPS cells. This may be the reason why the efficiency of reprogramming is extremely low. Several studies have demonstrated that when key components (such as p53 and p21) of the DNA damage machinery were deleted, the rate of iPS cell generation is significantly increased \[[@B88]-[@B94]\]. The detailed mechanism will be discussed by a separate review in this issue. It has been shown recently that vitamin C supplementation can improve reprogramming efficiency by alleviating p53-induced cell senescence and synergizing with epigenetic regulators \[[@B95]\]. However, it is dangerous to obtain rapid reprogramming at the cost of inappropriate suppression of DNA damage pathways. SV40 large T can disrupt the nuclear DNA-repair foci \[[@B96]\]. When it was added together with the four factors to reprogramme human fibroblast cells, iPS cell colonies emerged after 8 days but many of those iPS cells gained chromosomal abnormalities \[[@B97]\]. Thus, the intricate balance between safeguarding genome integrity and changing cell fate must be carefully maintained during reprogramming.

Future challenges
=================

By elucidating the mechanisms of how pluripotency factors interact with one another and with the genome, it should be possible to devise means to significantly improve reprogramming efficiency and speed. New interaction partners or pathways might provide explanations to species differences and provide the means to a defined *in vitro*culture of pluripotent cells. It remains to be seen whether human ES cells resemble an ICM or epiblast like stage, and whether or not that has any impact on their clinical applicability.

Several articles have reported that iPS cells are notably distinct from ES cells in terms of their gene expression, epigenetic profile, proliferative capacity and the susceptibility of their differentiated progeny to cellular senescence and apoptosis \[[@B82],[@B83],[@B98]-[@B100]\]. These differences need to be clearly defined and may become of importance if developmental research should be translated into the clinic. The definition of the cells in terms of pluripotency markers and the reproducibility of cell culture conditions will have a major impact on possible future therapeutical applications. There is a need for standardization in clinical protocols, which profits from fully defined media conditions allowing reproducible growth of pluripotent cells. Initial requirements, such as good manufacturing practice, are the same for human ES cells and human iPS cells \[[@B101]\]. However, iPS cells are certainly a step further away from clinical application than ES cells, as more parameters are yet to be characterized. First among these are issues of safety and efficacy. The earliest methods for the derivation of iPS cells used viral vectors, which may induce insertional mutagenesis and transgene reactivation. Alternative methods for inducing pluripotency without the use of gene insertion have been reported, though their efficiency needs improvement. Other safety criteria, such as long-term karyotypic stability, appropriate *in situ*localization, and potential differentiation of somatic cells derived from iPS cells, are to be investigated \[[@B102],[@B103]\].

Conclusions
===========

Ultimately, understanding of the underlying mechanisms of pluripotency will be able to guide the way to a safe and new cell-based medicine. The modelling of disease and normal development, if well understood, provides the chance to design completely new treatment modalities. Being autologous cells, iPS cells especially allow for a new individualised approach and are able to create a cell model as well as a cell source for each and every person.
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